CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The purpose of this study is to compare the usual approach of patients receiving best supportive care measures alone after exhausting all available treatments to adding two study drugs to the usual approach to treat colorectal cancer. Best supportive care is defined as supportive care with drugs and other treatments that may help to make you feel better or may improve your quality of life. This study will help the study doctors find out if this different approach is better than the usual approach.
The purpose of this study is to compare the effects on you and your liver cancer of adding a drug that is used on its own to treat this disease to a two-drug combination also used to treat liver cancer, compared to the two-drug combination alone.
The purpose of this study is to compare the usual approach of chemotherapy plus radiation therapy followed by limited surgery, to using a more intense combination chemotherapy treatment followed by limited surgery.
The study approach without radiation may improve your quality of life and be equally effective at shrinking or stabilizing your cancer.
The purpose of this study is to find out if the approach of avoiding or delaying surgery in patients who have a good response to treatment with chemotherapy and radiation is as good as the usual approach for your esophageal cancer and provides better quality of life.
The purpose of this study is to compare the usual approach of continuing Somatostatin Analogues (SSA) injections during and after Peptide Receptor Radionuclide Therapy (PRRT) to stopping SSA injections when PRRT begins in patients with neuroendocrine tumours (NET).
The purpose of this study is to find out what effects adding a new drug to the standard treatment has on you and your gastroesophageal cancer compared to the standard treatment given alone.
The purpose of this study is to determine which approach, less frequent or more frequent monitoring, will lead to better outcomes for patients with pancreatic cysts.
Currently, the effectiveness of any pancreatic cyst monitoring strategy is unknown. Patients and physicians are eager to learn which strategy is better for this very common condition.
The purpose of this study is to test if we can determine what kind of chemotherapy to offer patients based on whether or not circulating tumour DNA (ctDNA) is found in a blood test taken after surgery for colon cancer.
Using ctDNA testing to determine what kind of chemotherapy to use is a new approach. This approach seems promising, but it is not clear if it can offer better results than standard treatment.
The purpose of this study is to compare a retreatment with Peptide Receptor Radionuclide Therapy (PRRT) to the standard treatment for your neuroendocrine cancer.
The drug being studied is a new type of drug approved for the treatment of neuroendocrine tumours (NETs). The new drug has been shown to shrink tumours in many people and seems promising, but it is not clear if receiving this drug again can offer better results than standard treatment.
